Tech Company Financing Transactions

Dyne Therapeutics Funding Round

Dyne Therapeutics, based in Waltham, secured $115 million in funding from Surveyor Capital, Vida Ventures and Atlas Venture.

Transaction Overview

Company Name
Dyne Therapeutics
Announced On
8/11/2020
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Undisclosed
Investors

Surveyor Capital (Lead Investor)

Vida Ventures (Lead Investor)

Atlas Venture (Jason Rhodes)

Forbion Capital Partners (Dirk Kersten)

Franklin Templeton

Logos Capital

MPM Capital (Ed Hurwitz)

Wellington Management Company

Proceeds Purpose
The company intends to use the funds to accelerate the development of its pipeline of muscle disease therapies, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as additional indications, including cardiac and metabolic muscle diseases.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
830 Winter St.
Waltham, MA 02451
USA
Phone
(781) 786-8230
Website
www.dyne-tx.com
Email Address
[email protected]
Overview
Dyne Therapeutics (Nasdaq: DYN) was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
Profile
Dyne Therapeutics LinkedIn Company Profile
Social Media
Dyne Therapeutics Company Twitter Account
Company News
Dyne Therapeutics News
Facebook
Dyne Therapeutics on Facebook
YouTube
Dyne Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Joshua Brumm
  Joshua Brumm LinkedIn Profile  Joshua Brumm Twitter Account  Joshua Brumm News  Joshua Brumm on Facebook
Chief Operating Officer
Susanna High
  Susanna High LinkedIn Profile  Susanna High Twitter Account  Susanna High News  Susanna High on Facebook
Chief Scientific Officer
Romesh Subramanian
  Romesh Subramanian LinkedIn Profile  Romesh Subramanian Twitter Account  Romesh Subramanian News  Romesh Subramanian on Facebook
Vice President
John Davis
  John Davis LinkedIn Profile  John Davis Twitter Account  John Davis News  John Davis on Facebook
Vice President
Molly White
  Molly White LinkedIn Profile  Molly White Twitter Account  Molly White News  Molly White on Facebook
Vice President
Daniel Wilson
  Daniel Wilson LinkedIn Profile  Daniel Wilson Twitter Account  Daniel Wilson News  Daniel Wilson on Facebook
VP - Administration
Rick Scalzo
  Rick Scalzo LinkedIn Profile  Rick Scalzo Twitter Account  Rick Scalzo News  Rick Scalzo on Facebook
VP - Bus. Development
Jonathan McNeill
  Jonathan McNeill LinkedIn Profile  Jonathan McNeill Twitter Account  Jonathan McNeill News  Jonathan McNeill on Facebook
VP - Bus. Development
Chris Mix
  Chris Mix LinkedIn Profile  Chris Mix Twitter Account  Chris Mix News  Chris Mix on Facebook
VP - Finance
Gene Kim
  Gene Kim LinkedIn Profile  Gene Kim Twitter Account  Gene Kim News  Gene Kim on Facebook
VP - Manufacturing
John Najim
  John Najim LinkedIn Profile  John Najim Twitter Account  John Najim News  John Najim on Facebook
VP - R & D
Oxana Beskrovnaya
  Oxana Beskrovnaya LinkedIn Profile  Oxana Beskrovnaya Twitter Account  Oxana Beskrovnaya News  Oxana Beskrovnaya on Facebook
VP - R & D
Mo Qatanani
  Mo Qatanani LinkedIn Profile  Mo Qatanani Twitter Account  Mo Qatanani News  Mo Qatanani on Facebook
VP - Regulatory Affairs
Debra Feldman
  Debra Feldman LinkedIn Profile  Debra Feldman Twitter Account  Debra Feldman News  Debra Feldman on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/11/2020: GoSite venture capital transaction
Next: 8/11/2020: WorkPatterns venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.